Search tips
Search criteria 


Logo of actafjournal home pagethis articleInternational Union of Crystallographysearchsubscribearticle submission
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008 June 1; 64(Pt 6): 531–532.
Published online 2008 May 23. doi:  10.1107/S1744309108013444
PMCID: PMC2496868

Crystallization and preliminary X-ray structural studies of human prouroguanylin


Uroguanylin, which serves as an endogenous ligand of guanylyl cyclase C, is initially secreted in the form of a precursor, prouroguanylin. The N-terminal region of prouroguanylin interacts with the mature portion of prouroguanylin during the folding pathway. Here, a preliminary X-ray crystallographic study of prouroguanylin is presented. Prouroguanylin was refolded, purified and crystallized using the hanging-drop vapour-diffusion method. Prouroguanylin crystals were cryocooled and used for data collection. The diffraction data showed that the crystals belonged to space group P6122, with unit-cell parameters a = b = 55.6, c = 157.7 Å, and diffracted to 2.5 Å resolution. The structure is currently being analyzed.

Keywords: prouroguanylin, precursor proteins, peptide hormones

1. Introduction

Many peptide hormones are expressed in vivo in the form of pre­cursor proteins, i.e. prohormones, which are subsequently processed into a biologically active form. However, the detailed role of the propeptides in the precursor proteins is still unclear. Uroguanylin has been identified as an endogenous ligand of guanylyl cyclase C (GC-C; Hamra et al., 1993 [triangle]; Miyazato et al., 1996 [triangle]), which plays a role in the regulation of water in the intestine and kidney by affecting the cystic fibrosis transmembrane conductance regulator chloride channel (CFTR; Chao et al., 1994 [triangle]). Uroguanylin consists of 16 amino-acid residues, contains two intramolecular disulfide bonds and is secreted as its precursor protein prouroguanylin, which has 86 amino-acid residues (Miyazato et al., 1996 [triangle]; Fig. 1 [triangle]). The mature form of uro­guanylin does not possess sufficient information to permit the adaptation of its native conformation and to assume the correct disulfide pairing during folding. Uroguanylin requires the assistance of a propeptide from prouroguanylin for correct folding with native disulfide pairing (Hidaka et al., 1998 [triangle], 2000 [triangle]; Schulz et al., 1999 [triangle]). Little information is available about the functional sites/regions of the propeptide that are involved in this chaperone function.

Figure 1
Primary structure of prouroguanylin, a precursor of uroguanylin. The 2K mutant (a Q51K/A55K double mutant) was used for crystallization. Q51 and A55 are underlined.

To further investigate the chaperone function of the propeptide, we conducted X-ray crystallographic analysis of a prouroguanylin mutant.

2. Materials and methods

2.1. Expression of prouroguanylin

Wild-type human prouroguanylin was produced as inclusion bodies and the solubility of the refolding intermediates was very low; therefore, the wild-type protein could not be prepared in good yield. The Q51K/A55K mutant (2K mutant) was designed to increase the solubility of prouroguanylin. Escherichia coli BL21 (DE3) cells transformed with pET25b containing the 2K mutant cDNA were grown at 310 K in 2×YT medium (1 l) supplemented with ampicillin (50 mg ml−1), harvested by centrifugation after 18 h and lysed by sonication after resuspension in buffer A (100 mM Tris–HCl pH 7.4 and 300 mM NaCl). The mixture was centrifuged (10 000g for 20 min) and the 2K mutant was obtained as an insoluble material. The yield of the 2K mutant was approximately 12–15 mg from 1 l culture medium.

2.2. Protein refolding and purification

The recombinant 2K mutant, which was obtained as insoluble material, was dissolved in 30 ml 0.1 M Tris–HCl pH 8.0 containing 8 M urea and 10 mM DTT and kept at 323 K for 1 h. After centrifugation, the supernatant was applied onto a column of Cosmosil 140C18-OPN (10 ml; Nacarai Tesque, Kyoto, Japan) which was pre-equilibrated and washed with 50 ml 20% acetonitrile in 0.05% trifluoroacetic acid (TFA). The adsorbed proteins were eluted with 80% acetonitrile in 0.05% TFA and collected. The protein was further purified by HPLC using Cosmosil 5C18-AR (8 × 250 mm; Nacalai Tesque Inc., Kyoto, Japan). The HPLC apparatus consisted of a Waters 600 multisolvent delivery system (Millipore) equipped with a Hitachi L-4000 UV detector and a D-7500 chromato-integrator (Tokyo, Japan). The proteins were eluted using a linear gradient of aceto­nitrile in 0.05% TFA at a flow rate of 2 ml min−1 increasing at a rate of 1% per minute from solvent A (0.05% TFA/H2O) to solvent B (0.05% TFA/CH3CN).

After vacuum drying, the dried material (2K mutant, 25 nmol) was dissolved in 150 ml 6 M urea, 0.05% TFA and diluted in 2.85 ml 50 mM Tris–HCl pH 8.0 in the presence of 2 mM GSH (glutathione, reduced form) and 1 mM GSSG (glutathione, oxidized form) at 293 K for 2 d. The protein was further purified by ion-exchange chromatography using a DE-52 column (Whatman International Ltd, England), concentrated to 10 mg ml−1 and dialyzed against 20 mM Tris–HCl pH 7.0.

2.3. Crystallization

Crystallization was performed at 293 K in sitting drops by the vapour-diffusion method using 24-well plates (TPP, Switzerland). Initial crystallization conditions were established using Wizard I and II screening kits (Emerald Biostructures). Hanging drops were obtained by mixing 2.5 µl protein solution (10 mg ml−1 in 20 mM Tris–HCl pH 7.0) and 2.5 µl reservoir solution and were equilibrated against 600 µl reservoir solution. Recently, we have reported that certain amino-acid derivatives such as glycine ethyl ester (GlyEE) promote protein crystallization with high reproducibility (Ito et al., 2008 [triangle]). The crystallization condition was refined by varying the concentration of protein and additives using GlyEE as well as the pH of the buffer. The best condition was determined as a protein solution containing 10 mg ml−1 protein in 20 mM Tris–HCl pH 7.0 and a reservoir solution containing 1.2 M NaH2PO4, 0.8 M K2HPO4, 0.1 M NaCl and 0.2 M GlyEE.

2.4. Data collection and processing

All diffraction data for the 2K mutant crystal were collected under cryogenic conditions from crystals soaked in a cryoprotectant buffer containing 25%(v/v) glycerol and cooled to 100 K in a nitrogen-gas stream. Diffraction images were collected using an R-AXIS V (Rigaku) detector at the BL38B1 station at SPring-8. The diffraction data were autoindexed and integrated using the program MOSFLM (Leslie, 1992 [triangle]) and scaled, reduced and analyzed with SCALA from the CCP4 package (Collaborative Computational Project, Number 4, 1994 [triangle]). Crystal data and relevant statistics are given in Table 1 [triangle].

Table 1
Crystal data and diffraction data statistics

2.5. Results and discussion

The prouroguanylin crystals were analyzed by X-ray diffraction and belonged to space group P6122 or P6522, as deduced from systematic absences, with unit-cell parameters a = b = 55.6, c = 157.7 Å (Table 1 [triangle]). One molecule can be accommodated per asymmetric unit, suggesting a V M value of 3.7 Å3 Da−1 and a solvent content of 66.4%. A full data set was collected to 2.65 Å resolution. A total of 90 669 reflections were measured, including 4689 unique reflections. The completeness was 99.9%, with a multiplicity of 19.3 and an R merge of 6.2%.

Molecular-replacement calculations were performed with AMoRe (Navaza, 1994 [triangle]) as implemented in the CCP4 suite using the NMR structure of proguanylin (PDB code 1o8r), which is also the precursor protein of an endogenous ligand of GC-C and shows 38% identity to prouroguanylin, as a starting model. A distinct peak was found with a correlation coefficient of 34.8% and an R factor of 56.2% after translation-function calculations within the resolution range 15–3.5 Å. The space group was determined to be P6122. Structure determination and refinement are currently under way.


  • Chao, A. C., de Sauvage, F. J., Dong, Y. J., Wagner, J. A., Goeddel, D. V. & Gardner, P. (1994). EMBO J.13, 1065–1072. [PubMed]
  • Collaborative Computational Project, Number 4 (1994). Acta Cryst. D50, 760–763. [PubMed]
  • Hamra, F. K., Forte, L. R., Eber, S. L., Pidhorodeckyj, N. V., Krause, W. J., Freeman, R. H., Chin, D. T., Tompkins, J. A., Fok, K. F., Smith, C. E., Duffin, K. L., Siegel, N. R. & Currie, M. G. (1993). Proc. Natl Acad. Sci. USA, 90, 10464–10468. [PubMed]
  • Hidaka, Y., Ohno, M., Hemmasi, B., Hill, O., Forssmann, W. G. & Shimonishi, Y. (1998). Biochemistry, 37, 8498–8507. [PubMed]
  • Hidaka, Y., Shimono, C., Ohno, M., Okumura, N., Adermann, K., Forssmann, W. G. & Shimonishi, Y. (2000). J. Biol. Chem.275, 25155–25162. [PubMed]
  • Ito, L., Kobayashi, T., Shiraki, K. & Yamaguchi, H. (2008). J. Synchrotron Rad.15, 316–318. [PubMed]
  • Leslie, A. G. W. (1992). Jnt CCP4/ESF–EACBM Newsl. Protein Crystallogr.26
  • Miyazato, M., Nakazato, M., Yamaguchi, H., Date, Y., Kojima, M., Kangawa, K., Matsuo, H. & Matsukura, S. (1996). Biochem. Biophys. Res. Commun.219, 644–648. [PubMed]
  • Navaza, J. (1994). Acta Cryst. A50, 157–163.
  • Schulz, A., Marx, U. C., Hidaka, Y., Shimonishi, Y., Rösch, P., Forssmann, W. G. & Adermann, K. (1999). Protein Sci.8, 1850–1859. [PubMed]

Articles from Acta Crystallographica Section F: Structural Biology and Crystallization Communications are provided here courtesy of International Union of Crystallography